

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/583,590
				Filing Date	06/19/2006
				First Named Inventor	Wilfried Braje et al.
				Group Art Unit	Unknown 1624
				Examiner Name	Unknown Coleman
Sheet	1	of	2	Attorney Docket No.	ABB10010P00962US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
**	/B.C./	WO 96/02519	02/01/1996	BASF Aktiengesellschaft		
**	/B.C./	WO 96/02520	02/01/1996	BASF Aktiengesellschaft		
**	/B.C./	WO 96/02249	02/01/1996	BASF Aktiengesellschaft		
**	/B.C./	WO 96/02246	02/01/1996	BASF Aktiengesellschaft		
**	/B.C./	WO 99/02503	01/21/1999	BASF Aktiengesellschaft		
**	/B.C./	WO 00/21951	04/20/2000	SmithKline Beechman PLC		
	/B.C./	WO 02/40471	05/23/2002	SmithKline Beechman PLC		
	/B.C./	WO 03/68732	08/21/2003	Glaxo Group Limited		
	/B.C./	WO 03/68751	08/21/2003	Glaxo Group Limited		
	/B.C./	WO 03/68752	08/21/2003	Glaxo Group Limited		
	/B.C./	WO 02/40471	05/23/2002	SmithKline Beechman PLC		
	/B.C./	WO 01/51181	04/15/2001	Glaxo Group Limited		
**	/B.C./	DE 10 131 543	01/16/2003	Abbott Laboratories		

Examiner Signature	/Brenda Coleman/	Date Considered	08/29/2011
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed

** structures and abstract only



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/583,590
				Filing Date	06/19/2006
				First Named Inventor	Wilfried Braje et al.
				Group Art Unit	Unknown 1624
				Examiner Name	Unknown Coleman
Sheet	2	of	2	Attorney Docket No.	ABB10010P00962US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.C./		SCHWARTZ J C ET AL <i>The Dopamine D3 Receptor as a Target for Antipsychotics</i> Novel Antipsychotic Drugs, H.Y. Meltzer, ed., Raven Press, New York (1992) pp. 135-144	
/B.C./		DOOLEY M ET AL <i>Pramipexole A Review of its Use in the Management of Early and Advanced Parkinson's Disease</i> Drugs and Aging Vol. 12 (1998) pp. 495-514	
/B.C./		JOYCE J N ET AL <i>The Dopamine D3 Receptor as a therapeutic Target for Antipsychotic and Antiparkinsonian Drugs</i> Pharmacology and Therapeutics Vol. 90 (2001) pp. 231-259	
/B.C./		SOKOLOFF P ET AL <i>Localization and Function of the D3 Dopamine Receptor</i> Arzneim. Forsch./Drug Res. Vol. 42(1) (1992) pp. 224-230	
/B.C./		SOKOLOFF P ET AL <i>Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics</i> Nature Vol. 347 (1990) pp. 146-151	
Examiner Signature	/Brenda Coleman/		Date Considered 08/29/2011

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.